On Jan 08, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced encouraging top-line results from a phase Ib study (n=50) on APD334 being developed for the treatment of autoimmune diseases. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) belongs to Healthcare sector. Its weekly performance is 51.25%. On last trading day company shares ended up $5.43. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) distance from 50-day simple moving average (SMA50) is 31.40%. Hedge fund SPO … Continue reading Stocks Getting Investor’s Attention: Arena Pharmaceuticals (NASDAQ:ARNA), Oasis Petroleum (NYSE:OAS), The Royal Bank of Scotland (NYSE:RBS), WisdomTree Investments (NASDAQ:WETF), BPT